Holen Sie sich die Stockscreener-App
1.09
1.39%
0.01
NanoViricides Inc Aktie (NNVC) Neueste Nachrichten
Basic earnings per share (basic EPS) of NanoViricides, Inc. – HAM:NV3P - TradingView
NanoViricides Registers Phase II Ebola Trial for Oral Antiviral NV-387 in DRC - citybuzz -
NV3P Forecast — Price Target — Prediction for 2027 - TradingView
News by ACCESS Newswire on TradingView, 2026-09-08 - TradingView
While Measles Cases Continue to Increase in The USA and Globally, NanoViricides is Getting Ready for Clinical Trials of Its Revolutionary Broad-spectrum Drug Candidate NV-387 as A Treatment for Measles - ACCESS Newswire
NNVC Stock In The Limelight After This Analyst Sees A 350% Upside Potential – Everything To Know About Its Experimental Drug For Ebola - Stocktwits
Nanoviricides Stock Price Forecast. Should You Buy NNVC? - StockInvest.us
NanoViricides (AMEX: NNVC) May Generate Up to $4.4 Million Through Warrant Exercises - Kalkine Media
US FDA Has Granted A "Rare Pediatric Disease Drug" Designation for NV-387 As A Treatment for MeaslesEnables Priority Review Voucher - ACCESS Newswire
U.S. measles cases reach 2,903 by Aug. 27 as NanoViricides prepares a trial - Stock Titan
NanoViricides Inc. (NNVC) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
NanoViricides (NNVC) Chart: Ends Lower by 3.08% at $1.29 in the Latest Session; Technical View: the Supplied Trading Band Runs From $1.23 to $1.35 in the Available RecordFibonacci Fan - vinanet.vn
NanoViricides (NNVC) Results Breakdown: EPS Exceeds Its Estimate; After Earnings: Shares Move Higher 1.53%Subscription Growth Report - dars.gov.et
NanoViricides (NNVC) Technicals: Ends Up by 1.53% at $1.33 in the Latest Reading; Immediate View: Support at $1.26 and Resistance at $1.40 Frame the Range in the Available RecordWyckoff Accumulation - vinanet.vn
NanoViricides (NYSE American: NNVC) sets up warrant resale, up to $4.4M cash - Stock Titan
NanoViricides (NNVC) Levels: Finishes 0.82% Down at $1.33 at the Close; Chart Watch: Traders Can Monitor the $1.26-$1.40 Range in the Current UpdateHigh Conviction Picks - vinanet.vn
NanoViricides Prepares for Phase II Ebola Trial of Oral Drug Candidate in DRC - citybuzz -
Ebola outbreak has killed 2,325 as oral drug trial nears - Stock Titan
NNVC Stock Up 17% Today: What’s Driving The Rally? - Stocktwits
ETFs Investing in NanoViricides, Inc. Stocks - TradingView
NNVC Q2 2026 Earnings: EPS Surprise of 22.97% Bolsters Sentiment as Shares Rise 1.47%Interim Report - vinanet.vn
NNVC Q2 2026 Earnings: Narrower-Than-Expected Loss Marks 22.97% Positive SurpriseQuarterly Earnings Report - vinanet.vn
NanoViricides (NNVC) Edges Lower to $1.36 as Antiviral Developer Holds Support ZoneNews Sentiment - vinanet.vn
NanoViricides (NNVC) Slips to $1.36 as Biotech Micro-Cap Tests Key Support ZoneImpulse Wave - vinanet.vn
NanoViricides Has Received Regulatory Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo To Fight the Current Largest Ever and Expanding Ebola Outbreak - ACCESS Newswire
NanoViricides (NNVC) Dips 2.5% to $1.36 as Shares Approach Critical $1.29 SupportCollar Trade - vinanet.vn
NanoViricides, Inc. (NNVC) Stock Price, News, Quote & History - Yahoo! Finance Canada
NanoViricides Gets Approval for Phase II Ebola Trial in DRC, Offering Oral Treatment Option - citybuzz -
NanoViricides wins DRC approval for Phase II trial of NV-387 oral gummies for Ebola treatment - Bitget
DRC Ebola Outbreak Stands at 4,141 Cases as Oral Trial Gets Approval - Stock Titan
NNVC Q2 2026 Earnings: Loss Narrower Than Expected at -$0.11 Per Share, Stock Slips 2.1%Pre-Announcement Alert - vinanet.vn
NanoViricides (NNVC) Holds Gains at $1.54 as Shares Consolidate Between Support and ResistanceSweep Order Flow - vinanet.vn
NanoViricides Announces Pricing of $6 Million Registered Direct Offering and Concurrent Private Placement Priced at the Market Close - Watertown Public Opinion
NanoViricides (NNVC) Q2 2026 Earnings: Narrower-Than-Expected Loss but Shares Slip 1.94%Dividend Earnings Report - vinanet.vn
NanoViricides Inc (NNVC) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
NanoViricides Announces $3.8 Million Registered Direct Offering - TipRanks
NanoViricides Raises $3.8 Million in Registered Direct Offering; Adds Placement Agent and 30-Day Lock-Up - TradingView
Ebola outbreak death toll tops 1,300 as drug trial awaits approval - Stock Titan
NanoViricides Seeks Regulatory Approval for Ebola Trial of NV-387 Oral Gummies in DRC - citybuzz -
NanoViricides Inc (NNVC) Cash Flow - TradingKey
EDGAR Filing Documents for 0001104659-26-086797 - SEC.gov
Form 424B5 NanoViricides Inc For: 27 July By Investing.com - Investing.com Canada
Form 424B5 NANOVIRICIDES, INC. - StreetInsider
NanoViricides Announces Pricing of ~$3.8 Million Registered Direct Offering - ACCESS Newswire
As Ebola Death Toll Surpasses 930 Within Two Months, NanoViricides Has Applied to the DR Congo Regulatory Agency for Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola - ACCESS Newswire
NanoViricides, Inc. Revenue Breakdown – AMEX:NNVC - TradingView
NanoViricides Inc (NNVC) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
NNVC|NanoViricides Inc|Price:1.535|Chg%:+0.055 - TradingKey
NanoViricides Inc (NNVC) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
NanoViricides Inc (NNVC) Institutional Confidence - TradingKey
NanoViricides Raises $3.8 Million in Registered Direct Offering to Fund Antiviral Drug Development - citybuzz -
NanoViricides Seeks Approval for Phase II Ebola Trial in DRC Amid Ongoing Outbreak - citybuzz -
NanoViricides (NYSE:NNVC) Draws Attention After Clinical Update - Kalkine Media
DRC Ebola outbreak tops 930 deaths; NanoViricides seeks trial approval - Stock Titan
NanoViricides Seeks Approval for Ebola Treatment Trial - AllSci
Nanoviricides Company Profile & Introduction - Moomoo
NNVC Q2 2026 Earnings: Narrower Loss Beats Expectations as Drug Development ContinuesEstimate Revision Count - vinanet.vn
0.61%
3.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):